Print

Search Results: Treatment + Colorectal Cancer + Stage 4 (11 results)

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors

Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers.


A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation

Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation.


Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation

https://www.facingourrisk.org/research-clinical-trials/study/252/comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment

Treatment
Study for metastatic colorectal cancer that has not yet been treated

This study is being done to learn about the effects of using three study medicines together as treatment for metastatic colorectal cancer that has been previously untreated.


Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

https://www.facingourrisk.org/research-clinical-trials/study/274/treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

This study will compare a combination of drugs for people who have HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting.


Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks. 


Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced cancers

This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.


TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Treatment
Cancer treatment study for people with advanced solid tumors

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.


Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/181/combined-pembrolizumab-quavonlimab-mk-1308a-versus-other-treatments-in-people-with-msi-high-or-dmmr-stage-iv-colorectal-cancer

Treatment
Stage 4 colorectal cancer

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.


Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both Nivolumab and Relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.


Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study

https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study

Treatment

This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.


A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw

Treatment
People with metastatic colorectal cancer that is MSI-High

The purpose of this study is to compare the benefit of the combination of immunotherapy agents Nivolumab plus Ipilimumab in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using Nivolumab as a single therapy or chemotherapy. 


Additional Results on Clinicaltrials.gov Treatment + Colorectal Cancer + Stage 4
129 results

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT ID: NCT06300463 (https://classic.clinicaltrials.gov/show/NCT06300463)

Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
NCT ID: NCT03223779 (https://classic.clinicaltrials.gov/show/NCT03223779)

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
NCT ID: NCT06102902 (https://classic.clinicaltrials.gov/show/NCT06102902)

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
NCT ID: NCT03844750 (https://classic.clinicaltrials.gov/show/NCT03844750)

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
NCT ID: NCT05627635 (https://classic.clinicaltrials.gov/show/NCT05627635)

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
NCT ID: NCT06130280 (https://classic.clinicaltrials.gov/show/NCT06130280)

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
NCT ID: NCT04017650 (https://classic.clinicaltrials.gov/show/NCT04017650)

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
NCT ID: NCT04693377 (https://classic.clinicaltrials.gov/show/NCT04693377)

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
NCT ID: NCT05673148 (https://classic.clinicaltrials.gov/show/NCT05673148)

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT ID: NCT04599140 (https://classic.clinicaltrials.gov/show/NCT04599140)

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://classic.clinicaltrials.gov/show/NCT04899908)

Immunotherapy for Third Line Metastatic Colorectal Cancer
NCT ID: NCT04444622 (https://classic.clinicaltrials.gov/show/NCT04444622)

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
NCT ID: NCT06269978 (https://classic.clinicaltrials.gov/show/NCT06269978)

Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
NCT ID: NCT05672316 (https://classic.clinicaltrials.gov/show/NCT05672316)

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT06149481 (https://classic.clinicaltrials.gov/show/NCT06149481)

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
NCT ID: NCT05985954 (https://classic.clinicaltrials.gov/show/NCT05985954)

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT ID: NCT04587128 (https://classic.clinicaltrials.gov/show/NCT04587128)

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
NCT ID: NCT04853043 (https://classic.clinicaltrials.gov/show/NCT04853043)

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
NCT ID: NCT06011772 (https://classic.clinicaltrials.gov/show/NCT06011772)

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT ID: NCT05217446 (https://classic.clinicaltrials.gov/show/NCT05217446)

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)
NCT ID: NCT04895722 (https://classic.clinicaltrials.gov/show/NCT04895722)

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
NCT ID: NCT03659448 (https://classic.clinicaltrials.gov/show/NCT03659448)

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
NCT ID: NCT05308446 (https://classic.clinicaltrials.gov/show/NCT05308446)

Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
NCT ID: NCT02997228 (https://classic.clinicaltrials.gov/show/NCT02997228)

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers
NCT ID: NCT06194877 (https://classic.clinicaltrials.gov/show/NCT06194877)

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT ID: NCT05379595 (https://classic.clinicaltrials.gov/show/NCT05379595)

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
NCT ID: NCT04907539 (https://classic.clinicaltrials.gov/show/NCT04907539)

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
NCT ID: NCT06218914 (https://classic.clinicaltrials.gov/show/NCT06218914)

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT ID: NCT05631574 (https://classic.clinicaltrials.gov/show/NCT05631574)

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
NCT ID: NCT05239546 (https://classic.clinicaltrials.gov/show/NCT05239546)

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT ID: NCT05863195 (https://classic.clinicaltrials.gov/show/NCT05863195)

Intraperitoneal LSTA1 in CRS-HIPEC
NCT ID: NCT06216561 (https://classic.clinicaltrials.gov/show/NCT06216561)

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
NCT ID: NCT04668976 (https://classic.clinicaltrials.gov/show/NCT04668976)

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer
NCT ID: NCT05743036 (https://classic.clinicaltrials.gov/show/NCT05743036)

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
NCT ID: NCT05803382 (https://classic.clinicaltrials.gov/show/NCT05803382)

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
NCT ID: NCT05322590 (https://classic.clinicaltrials.gov/show/NCT05322590)

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT ID: NCT05200442 (https://classic.clinicaltrials.gov/show/NCT05200442)

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
NCT ID: NCT05576896 (https://classic.clinicaltrials.gov/show/NCT05576896)

Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
NCT ID: NCT03668431 (https://classic.clinicaltrials.gov/show/NCT03668431)

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
NCT ID: NCT05854498 (https://classic.clinicaltrials.gov/show/NCT05854498)

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
NCT ID: NCT03203525 (https://classic.clinicaltrials.gov/show/NCT03203525)

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer
NCT ID: NCT02600949 (https://classic.clinicaltrials.gov/show/NCT02600949)

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT04008030 (https://classic.clinicaltrials.gov/show/NCT04008030)

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
NCT ID: NCT04701476 (https://classic.clinicaltrials.gov/show/NCT04701476)

Infusion System for Hepatic Cancer
NCT ID: NCT04684862 (https://classic.clinicaltrials.gov/show/NCT04684862)

A Study to Investigate LYL845 in Adults With Solid Tumors
NCT ID: NCT05573035 (https://classic.clinicaltrials.gov/show/NCT05573035)

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
NCT ID: NCT03366155 (https://classic.clinicaltrials.gov/show/NCT03366155)

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
NCT ID: NCT05704985 (https://classic.clinicaltrials.gov/show/NCT05704985)

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
NCT ID: NCT04991948 (https://classic.clinicaltrials.gov/show/NCT04991948)

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
NCT ID: NCT06043713 (https://classic.clinicaltrials.gov/show/NCT06043713)

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
NCT ID: NCT06253520 (https://classic.clinicaltrials.gov/show/NCT06253520)

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT ID: NCT05838768 (https://classic.clinicaltrials.gov/show/NCT05838768)

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
NCT ID: NCT05425940 (https://classic.clinicaltrials.gov/show/NCT05425940)

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
NCT ID: NCT04426669 (https://classic.clinicaltrials.gov/show/NCT04426669)

EO4010 in Previously Treated Metastatic Colorectal Carcinoma
NCT ID: NCT05589597 (https://classic.clinicaltrials.gov/show/NCT05589597)

M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
NCT ID: NCT05286814 (https://classic.clinicaltrials.gov/show/NCT05286814)

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT ID: NCT03935893 (https://classic.clinicaltrials.gov/show/NCT03935893)

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://classic.clinicaltrials.gov/show/NCT05489211)

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://classic.clinicaltrials.gov/show/NCT04704661)

A Study of MGC026 in Participants With Advanced Solid Tumors
NCT ID: NCT06242470 (https://classic.clinicaltrials.gov/show/NCT06242470)

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://classic.clinicaltrials.gov/show/NCT05746897)

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
NCT ID: NCT06265285 (https://classic.clinicaltrials.gov/show/NCT06265285)

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT ID: NCT03965234 (https://classic.clinicaltrials.gov/show/NCT03965234)

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT ID: NCT05877599 (https://classic.clinicaltrials.gov/show/NCT05877599)

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
NCT ID: NCT04977453 (https://classic.clinicaltrials.gov/show/NCT04977453)

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT ID: NCT06105021 (https://classic.clinicaltrials.gov/show/NCT06105021)

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT ID: NCT05691491 (https://classic.clinicaltrials.gov/show/NCT05691491)

TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
NCT ID: NCT04873895 (https://classic.clinicaltrials.gov/show/NCT04873895)

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
NCT ID: NCT05736731 (https://classic.clinicaltrials.gov/show/NCT05736731)

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
NCT ID: NCT06107413 (https://classic.clinicaltrials.gov/show/NCT06107413)

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT ID: NCT05239143 (https://classic.clinicaltrials.gov/show/NCT05239143)

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT ID: NCT04929223 (https://classic.clinicaltrials.gov/show/NCT04929223)

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT ID: NCT05609370 (https://classic.clinicaltrials.gov/show/NCT05609370)

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
NCT ID: NCT06051695 (https://classic.clinicaltrials.gov/show/NCT06051695)

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
NCT ID: NCT06106308 (https://classic.clinicaltrials.gov/show/NCT06106308)

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT ID: NCT05733000 (https://classic.clinicaltrials.gov/show/NCT05733000)

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
NCT ID: NCT05954871 (https://classic.clinicaltrials.gov/show/NCT05954871)

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT ID: NCT06228326 (https://classic.clinicaltrials.gov/show/NCT06228326)

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT ID: NCT06047379 (https://classic.clinicaltrials.gov/show/NCT06047379)

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
NCT ID: NCT01365169 (https://classic.clinicaltrials.gov/show/NCT01365169)

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT ID: NCT05253651 (https://classic.clinicaltrials.gov/show/NCT05253651)

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT ID: NCT05806931 (https://classic.clinicaltrials.gov/show/NCT05806931)

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT ID: NCT04607421 (https://classic.clinicaltrials.gov/show/NCT04607421)

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
NCT ID: NCT04117087 (https://classic.clinicaltrials.gov/show/NCT04117087)

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT ID: NCT06026410 (https://classic.clinicaltrials.gov/show/NCT06026410)

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://classic.clinicaltrials.gov/show/NCT04771520)

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT ID: NCT04449874 (https://classic.clinicaltrials.gov/show/NCT04449874)

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
NCT ID: NCT04511039 (https://classic.clinicaltrials.gov/show/NCT04511039)

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
NCT ID: NCT05572684 (https://classic.clinicaltrials.gov/show/NCT05572684)

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID: NCT05576077 (https://classic.clinicaltrials.gov/show/NCT05576077)

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT ID: NCT06179160 (https://classic.clinicaltrials.gov/show/NCT06179160)

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors
NCT ID: NCT04083599 (https://classic.clinicaltrials.gov/show/NCT04083599)

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT04666688 (https://classic.clinicaltrials.gov/show/NCT04666688)

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT04913337 (https://classic.clinicaltrials.gov/show/NCT04913337)

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
NCT ID: NCT04329494 (https://classic.clinicaltrials.gov/show/NCT04329494)

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://classic.clinicaltrials.gov/show/NCT06270706)

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://classic.clinicaltrials.gov/show/NCT05277051)

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://classic.clinicaltrials.gov/show/NCT02632448)

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT ID: NCT05215574 (https://classic.clinicaltrials.gov/show/NCT05215574)

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
NCT ID: NCT06285097 (https://classic.clinicaltrials.gov/show/NCT06285097)

TAS102 in Combination With NAL-IRI in Advanced GI Cancers
NCT ID: NCT03368963 (https://classic.clinicaltrials.gov/show/NCT03368963)

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT ID: NCT05688280 (https://classic.clinicaltrials.gov/show/NCT05688280)

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
NCT ID: NCT03597581 (https://classic.clinicaltrials.gov/show/NCT03597581)

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
NCT ID: NCT04041310 (https://classic.clinicaltrials.gov/show/NCT04041310)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://classic.clinicaltrials.gov/show/NCT04585750)

Phase 2 Study of DKN-01 in Colorectal Cancer
NCT ID: NCT05480306 (https://classic.clinicaltrials.gov/show/NCT05480306)

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://classic.clinicaltrials.gov/show/NCT04140526)

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT ID: NCT03947385 (https://classic.clinicaltrials.gov/show/NCT03947385)

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
NCT ID: NCT05176483 (https://classic.clinicaltrials.gov/show/NCT05176483)

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT ID: NCT06328738 (https://classic.clinicaltrials.gov/show/NCT06328738)

A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors
NCT ID: NCT04892017 (https://classic.clinicaltrials.gov/show/NCT04892017)

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://classic.clinicaltrials.gov/show/NCT04319757)

A Study of ASP3082 in Adults With Previously Treated Solid Tumors
NCT ID: NCT05382559 (https://classic.clinicaltrials.gov/show/NCT05382559)

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT ID: NCT03526835 (https://classic.clinicaltrials.gov/show/NCT03526835)

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT ID: NCT04699188 (https://classic.clinicaltrials.gov/show/NCT04699188)

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT ID: NCT05592626 (https://classic.clinicaltrials.gov/show/NCT05592626)

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
NCT ID: NCT05185947 (https://classic.clinicaltrials.gov/show/NCT05185947)

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT ID: NCT05907304 (https://classic.clinicaltrials.gov/show/NCT05907304)

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT ID: NCT03485209 (https://classic.clinicaltrials.gov/show/NCT03485209)

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT ID: NCT05379985 (https://classic.clinicaltrials.gov/show/NCT05379985)

A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://classic.clinicaltrials.gov/show/NCT05107674)

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT ID: NCT03715933 (https://classic.clinicaltrials.gov/show/NCT03715933)

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT ID: NCT03785249 (https://classic.clinicaltrials.gov/show/NCT03785249)

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
NCT ID: NCT04553692 (https://classic.clinicaltrials.gov/show/NCT04553692)

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
NCT ID: NCT05091346 (https://classic.clinicaltrials.gov/show/NCT05091346)

A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://classic.clinicaltrials.gov/show/NCT05086692)

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT ID: NCT06322693 (https://classic.clinicaltrials.gov/show/NCT06322693)

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT ID: NCT02817633 (https://classic.clinicaltrials.gov/show/NCT02817633)


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.